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PLINICAL RESEARCH Clinical Trial
mprovement of Cardiovascular Risk Markers by
ioglitazone Is Independent From Glycemic Control
esults From the Pioneer Study
ndreas Pfützner, MD, PHD,*† Nikolaus Marx, MD,‡ Georg Lübben, MD,§ Matthias Langenfeld, MD,*
aniel Walcher, MD,‡ Thomas Konrad, MD, Thomas Forst, MD*
ainz, Rheinbach, Ulm, Aachen, and Frankfurt, Germany
OBJECTIVES This study was performed to assess whether the anti-inflammatory and antiatherogenic effects
of pioglitazone suggested by animal experiments are reproducible in man and independent
from improvements in metabolic control.
BACKGROUND Type 2 diabetes is associated with increased cardiovascular risk.
METHODS A total of 192 patients were enrolled into a six-month, prospective, open-label, controlled
clinical study. They were randomized to receive either pioglitazone (45 mg) or glimepiride (1
to 6 mg, with the intent to optimize therapy). Biochemical and clinical markers to assess
therapeutic effects included HbA1c, fasting glucose, insulin, adiponectin, lipids, high-
sensitivity C-reactive protein (hsCRP), intracellular adhesion molecule, vascular cell adhesion
molecule, vascular endothelial growth factor, fibrinogen, von Willebrand factor, matrix
metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-1, soluble CD40
ligand, and carotid intima-media thickness (IMT).
RESULTS The study was completed by 173 patients (66 female, 107 male; age [ SD]: 63  8 years;
disease duration: 7.2  7.2 years; HbA1c: 7.5  0.9%; pioglitazone arm: 89 patients). A
comparable reduction in HbA1c was seen in both groups (p  0.001). In the pioglitazone
group, reductions were observed for glucose (p  0.001 vs. glimepiride group at end point),
insulin (p  0.001), low-density lipoprotein/high-density lipoprotein ratio (p  0.001),
hsCRP (p  0.05), MMP-9 (p  0.05), MCP-1 (p  0.05), and carotid IMT (p  0.001),
and an increase was seen in high-density lipoprotein (p  0.001) and adiponectin (p 
0.001). Spearman ranks analysis revealed only one correlation between the reduction in
cardiovascular risk parameters and the improvement in the metabolic parameters (MMP-9
and fasting blood glucose, p  0.05)
CONCLUSIONS This prospective study gives evidence of an anti-inflammatory and antiatherogenic effect of
pioglitazone versus glimepiride. This effect is independent from blood glucose control and
may be attributed to peroxisome proliferator-activated receptor gamma activation. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.041Coll Cardiol 2005;45:1925–31) © 2005 by the American College of Cardiology Foundation
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tatients with type 2 diabetes mellitus exhibit an increased
ropensity to develop extensive arteriosclerosis with its
equelae, unstable angina pectoris and acute myocardial
nfarction (1,2). Over the last years, experimental data have
lluminated the role of inflammation in atherogenesis, while
linical studies have shown that this concept of inflamma-
ion in arteriosclerosis applies directly to human patients (3).
s such, increased serum levels of inflammatory biomarkers
f arteriosclerosis, like C-reactive protein, cytokines, like
umor necrosis factor-alpha or interleukin-6, as well as novel
arkers like monocyte chemoattractant protein (MCP)-1,
oluble CD40 ligand (sCD40L), and matrix metallopro-
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ermany; †University of Applied Sciences, Rheinbach, Germany; ‡University Hos-
ital, Ulm, Germany; §Takeda Pharma GmbH, Aachen, Germany; and ISF—
nstitute for Metabolic Research, Frankfurt, Germany. The study has been sponsored
y Takeda Pharma, Germany. Dr. Pfützner received research grants from Takeda. Dr.
orst received research grants and speaker fees from Takeda. Dr. Konrad received
esearch grants and speaker fees from Takeda. Dr. Marx received research grants and
peaker fees from Takeda. Dr. Lübben is employed by Takeda Pharma.w
Manuscript received October 12, 2004; revised manuscript received February 14,
005, accepted March 10, 2005.einases (MMP) have been shown to predict cardiovascular
isk and seem to reflect the overall burden of vascular disease
n patients. Interestingly, some of these markers are elevated
n patients with type 2 diabetes and insulin resistance,
ndicating a pivotal role of inflammation in this metabolic
isorder (4–6). Recent data suggest that the release of
nflammatory mediators like tumor necrosis factor-alpha
nd interleukin-6 from the visceral adipose tissue as well as
n activation of vascular cells itself contribute to the inflam-
atory state in these patients with metabolic syndrome.
herefore, enhanced serum levels of sCD40L may reflect
ndothelial and platelet activation in diabetic subjects, while
ncreased MMP-9 levels suggest the presence of unstable
laques with activated monocytes/macrophages (7–11).
oreover, elevated soluble adhesion molecules like soluble
ntracellular adhesion molecule (sICAM) and soluble vas-
ular cell adhesion molecule (sVCAM) are markers of
ndothelial dysfunction in these patients. Given the in-
reased risk of diabetic patients for macrovascular events,
herapeutic strategies that limit inflammation in the vessel
all and reduce serum levels of inflammatory surrogate
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Cardiovascular Risk Improvement by Pioglitazone June 21, 2005:1925–31arameters have been considered a promising tool to influ-
nce vascular disease in this high-risk population (12,13).
Recent experimental and clinical data suggest that a novel
roup of antidiabetic agents, thiazolidinediones (TZDs),
ike pioglitazone and rosiglitazone, may exhibit anti-
nflammatory properties in the vessel wall (14,15). These
gents act via the nuclear transcription factor peroxisome
roliferator-activated receptor gamma (PPAR) and, in
ddition to their metabolic action, have been shown to
egulate the expression of various target genes in vascular
ells in vitro and in vivo, subsequently limiting inflamma-
ory cell activation and lesion formation during atherogen-
sis. Furthermore, clinical data suggest that TZDs reduce
nflammatory biomarkers of arteriosclerosis, like C-reactive
rotein or sCD40L, in treated patients, thus potentially
odulating their cardiovascular risk (16–19). Still, most of
hese studies were placebo-controlled and, as such, did not
llow the dissection of metabolic from nonmetabolic TZDs’
ffects, because TZD treatment, compared to placebo,
ignificantly improved glucose metabolism in all of these
tudies. Therefore, we performed a six-month prospective,
andomized, controlled trial to compare the effect of piogli-
azone and sulfonylurea treatment on inflammatory bio-
arkers of arteriosclerosis, attempting to achieve compara-
le improvement in blood glucose control in both treatment
roups.
ETHODS
he prospective randomized monocentric study was ap-
roved by the responsible ethics committee and was per-
ormed in accordance with the Declaration of Helsinki and
he guidelines for good clinical practice. All patient exam-
nations were performed at the Clinical Department of the
nstitute for Clinical Research and Development (IKFE),
ainz, Germany. After written informed consent was
btained, 192 orally treated patients with type 2 diabetes
ithout prior TZD treatment were enrolled into the trial.
fter randomization, they either received a fixed dose of
Abbreviations and Acronyms
HDL  high-density lipoprotein
hsCRP  high-sensitivity C-reactive protein
ICAM  intracellular adhesion molecule
IMT  intima-media thickness
LDL  low-density lipoprotein
MCP  monocyte chemoattractant protein
MMP  matrix metalloproteinase
PPAR  peroxisome proliferator-activated receptor
gamma
PROactive  Prospective Pioglitazone Clinical Trial in
Macrovascular Events
sCD40L  soluble CD40 ligand
TZD  thiazolidinedione
VCAM  vascular cell adhesion molecule
VEGF  vascular endothelial growth factorioglitazone (45 mg/day) in the morning or glimepiride (1 io 6 mg/day), titrated for optimal glycemic control. Inclu-
ion criteria included an age of 40 to 75 years, HbA1c: 6.6%
o 9.9%, absence of significant hepatic or renal disease,
bsence of congestive heart failure (New York Heart Asso-
iation functional class II to IV), no cigarette smoking, and
o known carotid artery disease. All study measurements
ere obtained at study entry and after 26  2 weeks. In
rder to improve metabolic control, individual medical
dvice was given to every patient throughout the study. In
he pioglitazone group, other additional oral antidiabetic
herapy was permitted except for metformin, while only
ZDs were excluded for additional treatment in the
limepiride group. All blood draws and measurements were
erformed in the morning after fasting of the patients from
idnight onward.
iochemical parameters. HbA1c was determined by
eans of high-pressure liquid chromatography (Adams
MA1c, Menarini Diagnostics, Florence, Italy). Therapy
esponse was defined as an absolute decrease in HbA1c from
aseline by at least 0.6% (normal reference range: 4.2% to
.0%). Glucose was assessed using a standard glucose
xidase reference method (Ruhrtal Labortechnik,
ühnesee-Delecke, Germany), and lipids (total cholesterol,
ow-density lipoprotein [LDL], high-density lipoprotein
HDL], triglycerides) were measured by means of standard
ry chemistry methods (OSR, Olympus Diagnostica, Ham-
urg, Germany). Insulin was measured using a chemilumi-
escence method (Sciema, Mainz, Germany), PAI-I by
LISA (American Diagnostica, Pfungstadt, Germany), en-
othelin by ELISA (Biomedica, Vienna, Austria), and
diponectin by radioimmunoassay (Linco, St. Charles, Mis-
ouri); ELISAs from R&D Systems (Wiesbaden, Germany)
ere used for the determination of the following parame-
ers: ICAM, VCAM, vascular endothelial growth factor
VEGF], MMP-9, MCP-1. The sCD40L determinations
ere also performed by ELISA (Bender Medsystems, Vi-
nna, Austria). Turbimetric methods were used for the
ollowing parameters: high-sensitivity C-reactive protein
hsCRP) (Olympus, Hamburg, Germany), fibrinogen
Dade Behring, Schwalbach, Germany), and von-
illebrand factor (Instrumentation Laboratory GmbH,
irchheim, Germany).
High-sensitive C-reactive protein changes 15 mg/l
uring the observation period were attributed to other
nflammatory processes (flu, cold, and so on) and were
liminated before analysis.
arotid intima-media thickness (IMT). Carotid IMT
as evaluated at all time points by a single operator with
igh-resolution B-mode ultrasound on a single machine
Caris Plus, Esaote SpA, Genoa, Italy) with a 10-MHz
inear array transducer (LA 523). All recordings were
erformed in a standardized way, and readings were ana-
yzed by a physician blinded to patient profile and treatment
ssignment as described previously (20,21).
tatistical analysis. The analysis of efficacy is based on thentention-to-treat population, which consists of all patients
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June 21, 2005:1925–31 Cardiovascular Risk Improvement by Pioglitazoneho were treated and provided assessment of the laboratory
arameters at baseline and at end point of the study. All
nalyses were performed in an exploratory sense with
ppropriate parametrical and nonparametrical methods.
reatment groups were compared at baseline by using a
ilcoxon rank sum test for continuous variables and chi-
quare for categorical variables. Changes from baseline were
valuated by using analysis of covariance (ANCOVA)
odels with treatment groups as factor and baseline values
s covariate. The difference between treatment groups was
ssessed by using t test statistics for the hypothesis that
reatment group is a relevant factor in the model. Spearman
ank correlation coefficients were calculated to test for the
ndependence of the obtained results. All p values 0.05
ere interpreted as statistically significant.
ESULTS
f 192 patients, 179 were treated, and 173 were included
nto the intention-to-treat population. The most frequent
eason for early termination was patient decision (seven in
he pioglitazone group, three in the glimepiride group, p 
.226). The patient characteristics of the final analysis group
re given in Table 1. There were no significant differences
etween the treatment groups with regard to demographic
r treatment parameters. In total, 162 patients completed
he protocol. Glimepiride was administered at an average
aily dose of 2.7 1.6 mg. Both treatments were well
olerated, and no episode of severe hypoglycemia was
ecorded. Cardiac failure requiring hospitalization was re-
orted for two patients in the pioglitazone group.
ffects of pioglitazone and glimepiride on metabolic
arameters. There were no differences in all metabolic
arameters at baseline. In both groups an equal and signif-
cant improvement of HbA1c was observed (pioglitazone:
0.8  0.9%; glimepiride: 0.6  0.8%; p  0.001 vs.
aseline in both groups, no significant difference between
he groups at baseline and end point). Fasting glucose
ecreased at a higher extent in the pioglitazone group as
ompared to the glimepiride group (pioglitazone: 17.8 
Table 1. Patient Characteristics
Piogli
Age (yrs) 62
Gender (M:F)
Ethnicity (Caucasian:other)
Duration of diabetes (yrs) 7
HbA1c (%) 7.
HOMA-IR (mmol  U/ml/22.5) 6
Body mass index (kg/m2) 31
Systolic blood pressure (mm Hg) 1
Statin treatment (n, %)
ACE inhibitor/AT-1 antagonist (n, %)
Antiplatelet therapy (n, %)
Intima-media thickness (mm) 0.9
Plaques (n, %)ACE  angiotensin-converting enzyme; HOMA-IRHomeostat3.5 mg/dl; glimepiride: 4.8  30.8 mg/dl, p  0.01).
asting serum insulin concentrations decreased significantly
n the pioglitazone group (4.7  6.2 U/ml, p  0.001),
hile they remained unchanged in the glimepiride treat-
ent arm (0.4  5.7 U/ml, p  NS). A significant
ncrease of HDL cholesterol was seen in the pioglitazone
roup only (from 46  11 mg/dl to 54  13 mg/dl, p 
.001), while a decrease in total cholesterol was observed in
he glimepiride group only (from 228  38 mg/dl to 215 
9 mg/dl, p  0.001). Free fatty acids, triglycerides, and
diponectin improved significantly in the pioglitazone
roup only. A summary of the effects of both treatment
oieties on the metabolic markers is given in Table 2.
ffects of pioglitazone and glimepiride on cardiovascular
isk parameters. There were no differences in all cardio-
ascular risk parameters at baseline. For the remaining
roup, a significant reduction of hsCRP was seen after six
onths of therapy in the pioglitazone arm (0.10  2.25
g/dl, 29%, end point vs. baseline, p  0.001), while no
uch change could be seen during glimpiride treatment
0.24  4.04 mg/dl, 4%, p  NS). Treatment with
ioglitazone significantly decreased MMP-9 and MCP-1
oncentrations, while glimepiride did not induce changes in
hese parameters. At end point, there were significant
ifferences between the groups for both MCP-1 and
MP-9 in favor of pioglitazone (p  0.05 in both cases).
o significant changes or differences were observed for
CD40L, VEGF, ICAM, VCAM, fibrinogen, von-
illebrand factor, PAI-I, or endothelin-I. A summary of
he values at baseline and end point for both treatment
roups is given in Table 3, and the percent values for the
ignificantly changed parameters are given in Figure 1.
While both groups were comparable at baseline, substan-
ial regression of carotid IMT was seen in the pioglitazone
reatment arm only (54 59 m, p 0.001 vs. baseline).
he minor changes observed in the glimepiride group did
ot reach the level of statistical significance (11  58 m,
 0.001 between the groups at end point). Spearman
orrelation revealed a correlation between MCP-1 and
e Group
89)
Glimepiride Group
(n  84) p Value
8.4 63.0  7.4 NS
4 52:32 NS
81:3 NS
7.9 6.9  6.5 NS
0.85 7.44  0.89 NS
4.1 5.8  3.7 NS
5.0 31.8  4.3 NS
21 148  20 NS
%) 13 (15%) NS
%) 41 (49%) NS
%) 26 (31%) NS
0.149 0.924  0.150 NS
%) 36 (43%) NStazon
(n 
.2 
55:3
88:1
.4 
52 
.2 
.7 
49 
18 (20
52 (58
25 (28
49 
47 (53sis Model Assessment for insulin resistance.
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Cardiovascular Risk Improvement by Pioglitazone June 21, 2005:1925–31arotid IMT in the pioglitazone arm (p  0.05), while no
orrelation was seen between IMT reduction and hsCRP,
MP-9, or any of the other parameters. The observed
hanges were independent from the improvement of long-
erm glucose control, which is consistent with metabolic
ndings by other groups (22). A stratification into therapy
esponders (reduction in HbA1c 0.6%) and nonre-
ponders (reduction in HbA1c 0.6%) revealed no differ-
nce in the overall results (Fig. 2). Spearman correlation
nalyses between cardiovascular risk parameters and glyce-
ic control parameters resulted in only one correlation
reduction in MMP-9 and reduction in fasting glucose
ontrol, p  0.05) among the multiple possible combina-
ions (Table 4).
ISCUSSION
his prospective randomized controlled trial demonstrates
ignificant improvements of multiple cardiovascular risk
arkers during treatment with pioglitazone in comparison
o glimepiride administration over six months. Because
able 2. Changes in the Metabolic Parameters
Parameter
Baseline
Pioglitazone
(n  89)
Glimepe
(n  8
bA1c (%) 7.52  0.85 7.44 
asting serum glucose (mg/dl) 147  37 144 
asting serum insulin (U/ml) 17  9 16 
OMA-IR (mmol/l  U/ml) 6.2  4.1 5.8 
MI (kg/m2) 31.7  5.0 31.8 
otal cholesterol (mg/dl) 227  41 228 
DL cholesterol (mg/dl) 136  29 137 
DL cholesterol (mg/dl) 46  11 46 
DL/HDL ratio 3.1  0.9 3.2 
riglycerides (mg/dl) 190  109 202 
ree fatty acids (mmol/l) 0.54  0.21 0.55 
diponectin (mg/l) 6.7  3.4 6.5 
p  0.05; †p  0.005 vs. baseline; ‡p  0.001 vs. baseline.
BMI  body mass index; HDL  high-density lipoprotein; HOMA-IR  Hom
able 3. Changes in the Cardiovascular Risk Parameters
Parameter
Baseline
Pioglitazone
(n  89)
Glimeperide
(n  84)
MT (mm) 0.949  0.149 0.924  0.150
sCRP (mg/l) 3.49  3.26 3.26  4.31
CP-1 397  111 388  116
MP-9 373  147 354  179
CD40L 2.89  2.21 2.61  2.48
CAM (ng/ml) 299  60 310  78
CAM (ng/ml) 809  374 820  446
ibrinogen (g/l) 3.23  1.04 3.02  0.93
EGF (pg/ml) 415  245 409  235
on Willebrand factor 110  41 106  41
AI-1 (ng/ml) 45.3  7.9 46.3  7.4
ndothelin-I (pmol/l) 0.60  1.67 0.50  1.69
p  0.005 vs. baseline; †p  0.001 vs. baseline.
hsCRP  high-sensitivity C-reactive protein; ICAM  intracellular adhesion molecule
MP-9  matrix metalloproteinase 9; sCD40L  soluble CD40 ligand; VCAM  vascuetabolic control, as indicated by HbA1c values, was
omparably improved in both treatment arms, the observed
eneficial effects of pioglitazone on cardiovascular risk
arkers are suggested to be independent from overall
etabolic improvement but may rather be direct effects of
PAR activation. This hypothesis is supported by the fact
hat the observed changes were equally seen in therapy
esponders and nonresponders.
In comparison to glimepiride, pioglitazone treatment led
o a significant increase in HDL cholesterol and adiponec-
in, decrease in fasting glucose and insulin, significant
igher reduction of triglycerides, and a significant higher
eduction in the LDL/HDL ratio. These pronounced
ifferences between pioglitazone and sulfonylurea treatment
ave been consistently described by several groups in the
iterature (23–26). As one explanation for these findings,
lyceroneogenesis has been recently identified as a target of
ZDs in cultured adipocytes and fat tissues of Wistar rats.
he activation of glyceroneogenesis by TZDs occurs mainly
n visceral fat, the same fat depot that is specifically
End Point (26 Weeks)
p Value
(Between Groups
at End Point)
Pioglitazone
(n  89)
Glimepiride
(n  84)
6.71  0.89‡ 6.83  0.85‡ NS
128  29‡ 138  32 p  0.01
12  5‡ 17  10 p  0.001
3.9  1.9‡ 6.0  4.7 p  0.001
33.1  5.1 31.8  4.1 p  0.001
228  43 215  39 p  0.005
133  31 129  27 NS
54  13‡ 47  12 p  0.001
2.6  0.9* 2.9  0.7 p  0.05
168  102† 185  106‡ NS
0.50  0.20* 0.56  0.19 p  0.05
17.7  8.8‡ 6.0  2.6 p  0.001
tsis Model Assessment for insulin resistance; LDL  low-density lipoprotein.
End Point (26 Weeks)
p Value
(Absolute Changes,
Between Groups)
Pioglitazone
(n  89)
Glimepiride
(n  84)
0.893  0.144† 0.911  0.158 p  0.001
2.50  2.78† 3.13  3.50 p  0.05
368  99* 386  125 p  0.05
320  122* 362  179 p  0.01
3.15  2.71 2.98  2.60 NS
296  61 301  93 NS
813  467 800  463 NS
3.21  0.67 3.01  0.67 NS
409  243 402  206 NS
110  36 113  35 NS
45.1  8.5 46.8  5.6 NS
0.58  1.83 0.46  1.34 NSride
4)
0.89
34
9
3.7
4.3
38
25
14
0.9
111
0.18
3.4; IMT  intima-media thickness; MCP-1  monocyte chemoattractant protein 1;
lar cell adhesion molecule; VEGF  vascular endothelial growth factor.
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June 21, 2005:1925–31 Cardiovascular Risk Improvement by Pioglitazonemplicated in the progression of obesity to type 2 diabetes.
he main role of this metabolic pathway is to allow the
e-esterification of fatty acids via a futile cycle in adipocytes,
hus lowering fatty acid release into the plasma (27).
Inflammation plays an important role in arteriosclerosis,
nd measurement of hsCRP has become a novel but
merging tool for detecting individuals at high risk for
laque rupture. A randomized placebo-controlled study
ith different doses of rosiglitazone resulted in a decrease of
sCRP by 26.8% (4 mg) and 21.8% (8 mg) as compared to
he placebo group after 26 weeks in a Caucasian study
opulation (28). In another recent study performed in
apanese patients, treatment with 45 mg of pioglitazone
ignificantly reduced hsCRP by about 27% after three
onths of treatment, while no change occurred in the
lacebo comparator group. Independence from glucose
etabolism was suggested by ANCOVA analysis (29). In
ur study, baseline values were much higher than in the
igure 1. Mean of individual percent changes from baseline in selected
iochemical and clinical cardiovascular risk markers. hsCRP  high-
ensitivity C-reactive protein; IMT  carotid intima media thickness;
CP  monocyte chemoattractant protein; MMP  matrix metallopro-
einase.
igure 2. Stratification of percent changes in the cardiovascular risk
arkers according to therapeutic response (responders: absolute change ins
bA1c 0.6%; nonresponders: absolute change in HbA1c 0.6%).
bbreviations as in Figure 1.apanese study. The decrease in hsCRP by 29% during
ioglitazone treatment for the first time compares directly to
n equally effective antidiabetic comparator treatment that
id not induce any hsCRP change.
Substantial evidence supports a causal role for MCP-1
nd its receptor, CCR2, in the recruitment of monocytes
rom the circulation into atherosclerotic lesions. It has been
hown that activation of PPAR by synthetic ligands or
omponents of oxidized LDL reduces monocyte CCR2
xpression and blocks chemotaxis mediated by MCP-1 (30).
n parallel, activation of PPAR by pioglitazone may be
esponsible for the observed effects in our study. While no
uman data has been published yet about the influence of
ioglitazone on plasma MCP-1 levels, recent animal exper-
ments have indicated and demonstrated the prevention of
oronary arteriosclerosis by additional MCP-1–related anti-
nflammatory effects (down-regulation of CCR2 in circu-
ating and lesional monocytes) (16,31). In a small study
ithout an active comparator, six weeks of treatment with 4
g of rosiglitazone resulted in a significant improvement of
lasma MCP-1 in diabetic and nondiabetic subjects (17).
While no data have been published about the influence of
ioglitazone on plasma MMP-9 yet, two clinical reports
escribe the treatment effects of rosiglitazone on this
arker. In both cases, however, the studies were only
lacebo-controlled, and significant differences between the
reatment and comparator groups in long-term blood glu-
ose control and HbA1c were the consequence of this
esign. In one study, MMP-9 decreased in a dose-
ependent manner by 12.4% (4 mg dose) and 23.4% (8 mg
ose) during 26 weeks of therapy as compared to placebo
28). In the other trial, 4 mg of rosiglitazone twice daily led
o a significant reduction in MMP-9 by 24.1% (compared to
aseline) after 12 weeks (18). In the presented study,
owever, the 14.5% decrease in MMP-9 under pioglitazone
ompares to an increase by 2.8% with a glimepiride treat-
ent that results in the same HbA1c improvement.
No significant changes for sCD40L have been detected in
ur study. Reduction of this risk marker has been indepen-
ently reported after treatment with rosiglitazone and tro-
litazone. A reduction of sCD40 by 18.4% after six weeks of
reatment with rosiglitazone (4 mg twice a day) in compar-
son to placebo was reported by Marx et al. (19), and a mean
eduction by 29% in a heterogeneous diabetic population
as reported after troglitazone treatment for 12 weeks (12).
owever, in both study groups, the baseline values of
able 4. Spearman Analysis of the Relations Between Metabolic
nd Macrovascular Risk Markers
HbA1c
Fasting
Glucose
Fasting
Insulin HOMA-IR
sCRP 0.4477 0.6271 0.0745 0.2178
MP-9 0.6238 0.0379 0.1190 0.0589
CP-1 0.6075 0.2447 0.9249 0.6829
bbreviations as in Tables 2 and 3.CD40L were about twice as high as in our study popula-
t
i
P
e
P
e
P
r
p
r
c
e
T
i
t
a
d
a
g
c
h
fi
s
u
T
5
e
a
e
a
a
p
t
a
l
R
I
D
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
1930 Pfützner et al. JACC Vol. 45, No. 12, 2005
Cardiovascular Risk Improvement by Pioglitazone June 21, 2005:1925–31ion, which may explain our inability to observe any signif-
cant differences with regard to this parameter.
No influence of pioglitazone could also be observed on
AI-1 levels. Some authors describe reduction of PAI-1
xpression by TZDs (32,33), but others found no effect on
AI-1 expression at all (34). All these observations, how-
ver, have been made in vitro. Osman et al. (35) measured
AI-1 in type 2 patients with restenosis treated with
osiglitazone and could not find any changes in their study
opulation (35).
The major clinical finding of this study is a significant
eduction of carotid IMT, a strong and well described
linical predictor of cardiovascular risk and stroke (36,37),
xclusively in the pioglitazone-treated study population.
his finding and the parallel reduction in several biochem-
cal risk markers including hsCRP, MCP-1, MMP-9, and
he increase in adiponectin strongly suggest substantial
ntiarteriosclerotic actions of pioglitazone in vivo indepen-
ent from metabolic control. While anti-inflammatory and
ntiarteriosclerotic effects of pioglitazone have been sug-
ested after analysis of animal experiments (31), this is a first
omprehensive clinical investigation of these effects in
umans.
The answer to the question, whether the surrogate
ndings described in this study report can be translated into
ubstantial clinical outcome improvements, is currently
nder investigation in the Prospective Pioglitazone Clinical
rial in Macrovascular Events (PROactive) study with
,238 patients with type 2 diabetes. The cohort of patients
nrolled in PROactive is a typical type 2 diabetic population
t high risk of further macrovascular events. The primary
nd point is the time from randomization to occurrence of
new macrovascular event or death (38).
In conclusion, the presented study gives evidence of an
nti-inflammatory and potential antiatherogenic effect of
ioglitazone that is indicated by improvements in several
raditional and nontraditional cardiovascular risk markers
nd carotid IMT, independent of an improvement in
ong-term glycemic control.
eprint requests and correspondence: Dr. Andreas Pfützner,
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